Physician profile
Harsh Agrawal
NPI 1629397674
$10,564.77
in general payments reported to CMS, 2019-2025
26 companies · $2,552 in 2025
The $2,552 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,006 · 2020: $1,680 · 2021: $1,223 · 2022: $768 · 2023: $1,230 · 2024: $1,106 · 2025: $2,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,422 · Travel and Lodging: $1,465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,422.49 |
| Travel and Lodging | $1,464.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,325.35 | 2019-2025 | Triclip, Mitraclip, Amplatzer Amulet |
| Abiomed | $2,221.68 | 2019-2025 | Impella |
| Cardiovascular Systems INC. | $1,067.61 | 2019-2020 | |
| Boston Scientific Corporation | $741.91 | 2019-2025 | Watchman Flx, Watchman |
| Cathworks, INC. | $500.00 | 2021 | |
| Shockwave Medical, INC | $428.60 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $340.94 | 2022-2025 | Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Teleflex LLC | $324.55 | 2022-2023 | Turnpike |
| Medtronic, INC. | $286.87 | 2022-2024 | Corevalve Evolut R, Micra |
| Terumo Medical Corporation | $262.15 | 2020 | |
| Asahi Intecc USA, INC. | $166.59 | 2019 | |
| Medtronic Vascular, INC. | $142.71 | 2019 | |
| Amgen INC. | $137.19 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $130.08 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.85 | 2024-2025 | Lifevest |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $92.82 | 2025 | Indigo System |
| Kiniksa Pharmaceuticals International, Plc | $67.30 | 2024 | Arcalyst |
| Philips North America LLC | $55.02 | 2023-2024 | (Bq9) Coronary Ivus, (P84) Igt Devices Systems |
| Astrazeneca Pharmaceuticals LP | $36.76 | 2025 | Farxiga |
| Heartflow, INC. | $31.15 | 2025 | |
| Siemens Medical Solutions USA, INC. | $25.77 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.70 | 2025 | |
| Merck Sharp & Dohme LLC | $19.77 | 2025 | Verquvo |
| Octapharma USA, INC. | $18.70 | 2025 | Balfaxar |
| Angiodynamics, INC. | $13.70 | 2023 | Alphavac |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Agrawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.